JP6234381B2 - 包帯材システム - Google Patents
包帯材システム Download PDFInfo
- Publication number
- JP6234381B2 JP6234381B2 JP2014556758A JP2014556758A JP6234381B2 JP 6234381 B2 JP6234381 B2 JP 6234381B2 JP 2014556758 A JP2014556758 A JP 2014556758A JP 2014556758 A JP2014556758 A JP 2014556758A JP 6234381 B2 JP6234381 B2 JP 6234381B2
- Authority
- JP
- Japan
- Prior art keywords
- dressing
- strain
- skin
- edge
- applicator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000853 adhesive Substances 0.000 claims description 130
- 230000001070 adhesive effect Effects 0.000 claims description 130
- 239000000463 material Substances 0.000 claims description 87
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 237
- 238000011282 treatment Methods 0.000 description 148
- 208000027418 Wounds and injury Diseases 0.000 description 121
- 206010052428 Wound Diseases 0.000 description 114
- 230000035882 stress Effects 0.000 description 88
- 238000000034 method Methods 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 47
- 230000007246 mechanism Effects 0.000 description 39
- 239000013013 elastic material Substances 0.000 description 36
- 231100000241 scar Toxicity 0.000 description 36
- 208000032544 Cicatrix Diseases 0.000 description 22
- 230000037387 scars Effects 0.000 description 22
- 239000010410 layer Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 230000001969 hypertrophic effect Effects 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229920001296 polysiloxane Polymers 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 208000002260 Keloid Diseases 0.000 description 11
- 210000001117 keloid Anatomy 0.000 description 11
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 10
- 238000007906 compression Methods 0.000 description 10
- 230000006835 compression Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 206010040844 Skin exfoliation Diseases 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000036573 scar formation Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 208000002352 blister Diseases 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 230000001788 irregular Effects 0.000 description 6
- 230000035752 proliferative phase Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 229920002725 thermoplastic elastomer Polymers 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 230000000712 assembly Effects 0.000 description 5
- 238000000429 assembly Methods 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 208000011379 keloid formation Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920006132 styrene block copolymer Polymers 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 229920002367 Polyisobutene Polymers 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000036074 healthy skin Effects 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229920002799 BoPET Polymers 0.000 description 3
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 239000005041 Mylar™ Substances 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000282 nail Anatomy 0.000 description 3
- 239000011087 paperboard Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920003051 synthetic elastomer Polymers 0.000 description 3
- 239000005061 synthetic rubber Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 229920001634 Copolyester Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229920006169 Perfluoroelastomer Polymers 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 229920002614 Polyether block amide Polymers 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010048031 Wound dehiscence Diseases 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 229940010048 aluminum sulfate Drugs 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000504 antifibrinolytic agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920001973 fluoroelastomer Polymers 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108010046630 polymyxin B drug combination bacitracin Proteins 0.000 description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229940103255 polysporin Drugs 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 229940050271 potassium alum Drugs 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 229960001516 silver nitrate Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 239000012780 transparent material Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- 229950009819 zotarolimus Drugs 0.000 description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010023728 Alloderm Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108010001781 Apligraf Proteins 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XIIJQOYMVIJNEP-UHFFFAOYSA-N C1C2C(C3)C3CC12 Chemical compound C1C2C(C3)C3CC12 XIIJQOYMVIJNEP-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000510032 Ellipsaria lineolata Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000722985 Fidia Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 206010067193 Naevus flammeus Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003397 biobrane Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 108010045487 coagulogen Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000002026 familial multiple nevi flammei Diseases 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229920000431 shape-memory polymer Polymers 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F15/00—Auxiliary appliances for wound dressings; Dispensing containers for dressings or bandages
- A61F15/005—Bandage applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本願は、2012年2月8日に出願された米国仮出願第61/596,708号に対する35 U.S.C. §119(e)に基づく利益を主張するものであり、該仮出願の全体は参照により本明細書中に援用される。本願は、2011年8月11日に出願された米国特許出願第12/854,859および2012年1月6日に出願された米国特許出願第13/345,524に関連しており、これらの出願の全体は、参照により本明細書中に援用される。
本発明は、例えば、以下を提供する。
(項目1)
包帯材システムであって、
第1の縁および第2の縁と、接着剤を含む第1の面とを備える包帯材であって、上記第2の縁は、上記包帯材が非歪状態にあるとき、上記第1の縁に対して非平行かつ非直交である配向を有する、包帯材と、
上記包帯材に切り離し可能に取着され、上記包帯材の上記第1の縁および上記第2の縁を支持するフレームであって、外側縁と、内側縁と、上記内側縁によって囲繞される開口部とを備える、フレームと
を備える、システム。
(項目2)
上記フレームは、上記第1の面と反対の上記包帯材の第2の面に連結される、項目1に記載の包帯材システム。
(項目3)
上記包帯材は、円形または楕円形包帯材を備える、項目1または2に記載の包帯材システム。
(項目4)
上記包帯材は、上記包帯材を上記フレームから分離するように構成される剥離領域を備える、項目1から3のいずれかに記載の包帯材システム。
(項目5)
上記剥離領域は、ミシン目領域、穿孔領域のうちの少なくとも1つを備える、または埋設引張線を備える、項目1から4のいずれかに記載の包帯材システム。
(項目6)
上記剥離領域は、上記剥離領域に連結された引張タブを備える、項目4または5のいずれかに記載の包帯材システム。
(項目7)
上記第1の縁は、第1の曲率半径を伴う弧状縁を備える、項目1から6のいずれかに記載の包帯材システム。
(項目8)
上記第2の縁は、第2の曲率半径を伴う弧状縁を備える、項目7に記載の包帯材システム。
(項目9)
上記第2の曲率半径は、上記第1の曲率半径と異なる、項目8に記載の包帯材システム。
(項目10)
上記フレームの開口部を通して押動され、上記包帯材に歪を付与するように構成される、歪付与構造をさらに備える、項目1から9のいずれかに記載の包帯材システム。
(項目11)
上記フレームは、上記歪付与構造に接着されるように構成される、項目10に記載の包帯材システム。
(項目12)
上記フレームは、ベースと力学的相互嵌合を形成する、項目10に記載の包帯材システム。
(項目13)
歪付与構造は、ベースおよび隆起突出部を備える、項目10から12のいずれかに記載の包帯材システム。
(項目14)
上記隆起突出部は、上記ベースに直交する側壁を備える、項目13に記載の包帯材システム。
(項目15)
上記隆起突出部は、上記ベースと90度を上回る開放角を形成する側壁を備える、項目13に記載の包帯材システム。
(項目16)
上記隆起突出部は、上記ベースと90度未満の開放角を形成する側壁を備える、項目13に記載の包帯材システム。
(項目17)
上記歪付与構造は、上記包帯材の第2の面に対して押動するように構成される遠位面を備える、項目13から16に記載の包帯材システム。
(項目18)
上記歪付与構造の遠位面は、上記包帯材、上記フレームの開口部、上記ベース、または上記ベースとの交点における上記側壁の形状のうちの少なくとも1つに類似する一般的形状を備える、項目17に記載の包帯材システム。
(項目19)
上記歪付与構造および上記フレームは、概して、上記包帯材の第1および第2の縁に直交する均一歪付与力を上記包帯材に印加するように構成される、項目10に記載の包帯材システム。
(項目20)
上記歪付与構造および上記フレームは、上記包帯材の第1の縁に直交する第1の歪付与力を上記包帯材に印加し、上記包帯材の第2の縁に直交する第2の歪付与力を上記包帯材に印加するように構成され、上記包帯材の第2の歪付与力は、上記第2の縁の各側に位置する上記包帯材の第3および第4の縁に直交する上記包帯材への歪付与力を上回る、項目10に記載の包帯材システム。
(項目21)
上記包帯材を上記フレームから切断するように構成される切断構造をさらに備える、項目1から4のいずれかに記載の包帯材システム。
(項目22)
非歪円形または楕円形形状および歪円形または楕円形形状を伴う包帯材を備える包帯材システムであって、第1の横方向寸法上の歪は、上記第1の横方向寸法に整合、平行、または直交しない第2の横方向寸法上の歪と同一である、システム。
(項目23)
歪付与構造と、包帯材と、弾性包帯材を切り離し可能に保定するように構成されるフレームとを備える包帯材システムであって、上記歪付与構造および上記フレームは、上記包帯材の第1の縁に直交する第1の歪付与力を上記包帯材に印加し、上記包帯材の第2の縁に直交する第2の歪付与力を上記包帯材に印加するように構成され、上記包帯材の第2の歪付与力は、上記第2の縁の各側に位置する上記包帯材の第3および第4の縁に直交する上記包帯材への歪付与力を上回る、システム。
(項目24)
包帯材に歪を付与する方法であって、
第1の平面に位置する第1の軸に沿って、第1の包帯材領域に歪を付与するステップと、
上記第1の平面と異なる第2の平面に位置する第2の軸に沿って、第2の包帯材領域に歪を付与するステップであって、上記第2の包帯材領域は、上記第1の包帯材領域に連結される、ステップと、
上記第1の包帯材領域を治療部位に適用するステップと、
少なくとも一部の歪を上記第1の包帯材領域から剥離するステップと
を含む、方法。
(項目25)
第3の包帯材領域を上記第2の包帯材領域から分離し、上記第1の包帯材領域への少なくとも一部の歪を緩和させるステップをさらに含む、項目24に記載の方法。
(項目26)
上記第2の包帯材領域は、上記第1の包帯材領域を包囲する、項目24または25に記載の方法。
(項目27)
上記第3の包帯材領域は、上記第2の包帯材領域を包囲する、項目25に記載の方法。
(項目28)
上記第1の包帯材領域内の少なくとも一部を剥離するステップは、上記第2の包帯材領域内の実質的全歪を剥離する、項目24に記載の方法。
(項目29)
包帯材に歪を付与する方法であって、
一式の均一歪力を用いて包帯材に歪を付与するステップであって、第1の力は、上記包帯材の第1の縁に直交する配向を伴い、第2の力は、第2の縁に直交し、上記第1の力に等しく、上記第1の縁に対して非整合、非平行、かつ非直交する配向を有する、ステップと、
上記歪包帯材を治療部位に適用するステップと、
上記包帯材内の歪を緩和させ、圧縮力を上記治療部位に印加するステップと
を含む、方法。
(項目30)
上記包帯材は、円形または楕円形包帯材である、項目29に記載の方法。
Claims (15)
- 包帯材システムであって、前記包帯材システムは、
第1の縁および第2の縁と、接着剤を備える第1の面とを備える包帯材であって、前記第2の縁は、前記包帯材が非歪状態にあるとき、前記第1の縁に対して非平行かつ非直交である配向を有する、包帯材と、
前記包帯材に切り離し可能に取着され、前記包帯材の前記第1の縁および前記第2の縁を支持するフレームと、
前記包帯材の第1の縁に直交する第1の歪付与力を前記包帯材に印加し、前記包帯材の第2の縁に直交する第2の歪付与力を前記包帯材に印加するように構成されている歪付与構造と
を備える、包帯材システム。 - 前記包帯材は、円形または楕円形である、請求項1に記載の包帯材システム。
- 前記第1の縁は、第1の曲率半径を伴う弧状縁を備える、請求項1に記載の包帯材システム。
- 前記第2の縁は、第2の曲率半径を伴う弧状縁を備え、前記第2の曲率半径は、前記第1の曲率半径とは異なる、請求項3に記載の包帯材システム。
- 前記歪付与構造は、前記包帯材の第1および第2の縁に直交する均一歪付与力を印加するように構成されている、請求項1に記載の包帯材システム。
- 前記歪付与構造は、前記包帯材の第1の縁に直交する第1の歪付与力を印加することと、前記包帯材の第2の縁に直交し、かつ前記第1の歪付与力を上回る第2の歪付与力を前記包帯材の第2の縁に印加することとを行うように構成されている、請求項1に記載の包帯材システム。
- 前記包帯材は、前記包帯材を前記フレームから分離するように構成された剥離領域を備える、請求項1に記載の包帯材システム。
- 前記剥離領域は、ミシン目領域、穿孔領域のうちの少なくとも1つを備え、または引張線を備える、請求項7に記載の包帯材システム。
- 前記フレームは、前記歪付与構造に接着されるように構成されている、請求項1に記載の包帯材システム。
- 前記フレームは、外側縁と、内側縁と、前記内側縁によって囲繞された開口部とを備え、前記歪付与構造は、前記フレームの開口部を通して押動され、かつ、前記包帯材に歪を付与するように構成されている、請求項1に記載の包帯材システム。
- 歪付与構造は、ベースおよび隆起突出部を備える、請求項1に記載の包帯材システム。
- 前記フレームは、前記歪付与構造と力学的相互嵌合を形成する、請求項1に記載の包帯材システム。
- 前記フレームは、前記第1の面と反対の前記包帯材の第2の面に連結され、前記歪付与構造は、前記包帯材の第2の面に対して押動するように構成された遠位面を備える、請求項1に記載の包帯材システム。
- 前記歪付与構造の遠位面は、前記包帯材、前記フレームの開口部、前記ベース、または前記ベースとの交点における側壁の形状のうちの少なくとも1つに類似する一般的形状を備える、請求項13に記載の包帯材システム。
- 前記包帯材を前記フレームから切断するように構成された切断構造をさらに備える、請求項1に記載の包帯材システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596708P | 2012-02-08 | 2012-02-08 | |
US61/596,708 | 2012-02-08 | ||
PCT/US2013/025449 WO2014021934A2 (en) | 2012-01-06 | 2013-02-08 | Radially tensioned wound or skin treatment devices and methods |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015516820A JP2015516820A (ja) | 2015-06-18 |
JP2015516820A5 JP2015516820A5 (ja) | 2016-03-31 |
JP6234381B2 true JP6234381B2 (ja) | 2017-11-22 |
Family
ID=50028640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014556758A Active JP6234381B2 (ja) | 2012-02-08 | 2013-02-08 | 包帯材システム |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2811956B1 (ja) |
JP (1) | JP6234381B2 (ja) |
KR (1) | KR102107459B1 (ja) |
CN (1) | CN104507428B (ja) |
BR (1) | BR112014019587B1 (ja) |
HK (1) | HK1209016A1 (ja) |
WO (1) | WO2014021934A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10561359B2 (en) | 2011-12-02 | 2020-02-18 | Neodyne Biosciences, Inc. | Elastic devices, methods, systems and kits for selecting skin treatment devices |
US10213350B2 (en) | 2012-02-08 | 2019-02-26 | Neodyne Biosciences, Inc. | Radially tensioned wound or skin treatment devices and methods |
CA2959544A1 (en) | 2014-04-29 | 2015-11-05 | Roffe Medical Holdings Pty Ltd | Tissue closing method and apparatus |
JP6744310B2 (ja) * | 2014-12-19 | 2020-08-19 | スリーエム イノベイティブ プロパティズ カンパニー | 粘弾性創傷閉鎖ドレッシング |
CN105616071A (zh) * | 2016-03-20 | 2016-06-01 | 漳州卫生职业学院 | 带有控温、压力感应和血氧饱和度检测的耳再造耳托支架 |
EP3843645A4 (en) * | 2018-08-31 | 2022-05-11 | Zipline Medical, Inc. | CLOSURE DEVICES AND PROCEDURES FOR ULCERS AND IRREGULAR SKIN DEFECTS |
CN109394286A (zh) * | 2018-12-07 | 2019-03-01 | 中国人民解放军陆军军医大学第附属医院 | 基于3d打印技术的异形手术创口缝合装置及其制作方法 |
CN110169867B (zh) * | 2019-04-24 | 2024-08-02 | 浙江省人民医院 | 一种可调式螺旋敷贴 |
CN110151396A (zh) * | 2019-05-28 | 2019-08-23 | 杭州美灵达科技有限公司 | 一种带有敷料的医用弹性胶带 |
US20230040187A1 (en) * | 2019-12-10 | 2023-02-09 | Neodyne Biosciences, Inc. | Injection and infusion site treatment devices and methods |
US20220379018A1 (en) | 2019-12-10 | 2022-12-01 | Neodyne Biosciences, Inc. | Tensioned infusion systems with removable hubs |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022891B2 (en) * | 1996-05-10 | 2006-04-04 | Wallace J Beaudry | Dressing and an epidermal positioning mechanism and method for using same |
US6838589B2 (en) * | 2003-02-19 | 2005-01-04 | 3M Innovative Properties Company | Conformable wound dressing |
US20060037091A1 (en) | 2004-05-24 | 2006-02-16 | Gurtner Geoffrey C | Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring |
AU2007282013B2 (en) | 2006-08-03 | 2013-07-11 | The Board Of Trustees Of The Leland Stanford Junior University | Devices and bandages for the treatment or prevention of scars and/or keloids and methods and kits therefor |
US8592640B2 (en) * | 2009-08-11 | 2013-11-26 | Neodyne Biosciences, Inc. | Devices and methods for dressing applicators |
EP2579828B1 (en) * | 2010-06-14 | 2018-06-13 | Zipline Medical Inc. | Apparatus for inhibiting scar formation |
US8591447B2 (en) * | 2010-06-29 | 2013-11-26 | Jennifer DiGrazia | Wound and bandage protection system and method |
CA2824045C (en) | 2011-01-07 | 2019-04-09 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
US20130110026A1 (en) | 2011-07-27 | 2013-05-02 | Neodyne Biosciences, Inc. | Strained skin treatment devices and methods |
-
2013
- 2013-02-08 WO PCT/US2013/025449 patent/WO2014021934A2/en active Application Filing
- 2013-02-08 BR BR112014019587-0A patent/BR112014019587B1/pt active IP Right Grant
- 2013-02-08 JP JP2014556758A patent/JP6234381B2/ja active Active
- 2013-02-08 EP EP13825488.3A patent/EP2811956B1/en active Active
- 2013-02-08 KR KR1020147025268A patent/KR102107459B1/ko active IP Right Grant
- 2013-02-08 CN CN201380012873.8A patent/CN104507428B/zh active Active
-
2015
- 2015-10-07 HK HK15109784.4A patent/HK1209016A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN104507428A (zh) | 2015-04-08 |
EP2811956A2 (en) | 2014-12-17 |
EP2811956B1 (en) | 2017-08-16 |
WO2014021934A3 (en) | 2015-03-12 |
JP2015516820A (ja) | 2015-06-18 |
KR102107459B1 (ko) | 2020-05-07 |
EP2811956A4 (en) | 2016-03-23 |
BR112014019587B1 (pt) | 2022-01-11 |
BR112014019587A2 (pt) | 2017-06-20 |
KR20140122756A (ko) | 2014-10-20 |
BR112014019587A8 (pt) | 2017-07-11 |
WO2014021934A2 (en) | 2014-02-06 |
CN104507428B (zh) | 2017-09-12 |
HK1209016A1 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6234381B2 (ja) | 包帯材システム | |
US11357674B2 (en) | Radially tensioned wound or skin treatment devices and methods | |
US11013638B2 (en) | Wound or skin treatment devices and methods | |
US10561359B2 (en) | Elastic devices, methods, systems and kits for selecting skin treatment devices | |
US9241835B2 (en) | Wound or skin treatment devices with variable edge geometries | |
JP6375363B2 (ja) | 可変の縁の幾何学形状を有する創傷または皮膚治療デバイス | |
US20130110026A1 (en) | Strained skin treatment devices and methods | |
US9668922B2 (en) | Wound or skin treatment devices with variable edge geometries | |
CN115103639A (zh) | 注射和输注部位处理装置和方法 | |
US20220240935A1 (en) | Wound closure device with wide spaced microstructures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160205 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160205 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171024 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6234381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |